![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PegIFN alfa-2a (40KD) and ribavirin (P/R) in treatment-naive HCV genotype 1 (G1) patients: results from the ATLAS study
|
|
|
Reported by Jules Levin AASLD Nov 5-9 2011 SF
Norah Terrault, Curtis Cooper, Luis A Balart, Dominique G Larrey, Terry D Box, Eric Yoshida, Eric Lawitz, Peter Buggisch, Peter Ferenci, Martin Weltman,
Emily Labriola-Tompkins, Sophie Le Pogam, Isabel Najera, Denise Thomas, Greg Hooper, Nancy Shulman, Ying Zhang, Mercidita T Navarro, Chin Yin Lim, Ellen S Yetzer, Patrick Marcellin
From Jules: danoprevir is being developed being boosted by low dose, 100 mg, of ritonavir as are HIV protease inhibitors, and study results will be presented soon at a conference.
![AASLD1.gif](../images/110711/110711-12/AASLD1.gif)
![AASLD2.gif](../images/110711/110711-12/AASLD2.gif)
![AASLD3.gif](../images/110711/110711-12/AASLD3.gif)
![AASLD4.gif](../images/110711/110711-12/AASLD4.gif)
![AASLD5.gif](../images/110711/110711-12/AASLD5.gif)
![AASLD6.gif](../images/110711/110711-12/AASLD6.gif)
![AASLD7.gif](../images/110711/110711-12/AASLD7.gif)
![AASLD8.gif](../images/110711/110711-12/AASLD8.gif)
![AASLD9.gif](../images/110711/110711-12/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|